Antibody Sequencing Services2024-05-14T15:10:00-04:00

Antibody Sequencing Service.

REmAb® has been the world leading antibody sequencing service since 2015, with unmatched throughput and accuracy. De novo Antibody Sequencing determines the amino acid sequence of monoclonal antibodies using mass spectrometry. Our proprietary antibody protein sequencing technology offers full coverage, speed and leucine-isoleucine determination.

How Antibody Sequencing Works.

The REmAb® de novo antibody sequencing workflow delivers the complete antibody sequence, including complementarity determining regions (CDR), with unparalleled accuracy and reliability. Starting with just 50μg of purified antibody, the sample undergoes multi-enzyme digestions. The fragments are measured with LC-MS/MS for de novo sequencing of the peptides. These peptides are analyzed by Rapid Novor’s suite of bioinformatics algorithms to assemble the full-length heavy and light chain antibody sequences. Monoclonal antibody sequencing works on any species and isotype.

Our antibody sequencing platform delivers high quality coverage across the full antibody sequence, variable region and constant region, with hundreds of overlapped peptides. This is a de novo sequencing method – it does not require database or sequence data for reference or homology.

monoclonal antibody sequencing workflow through de novo protein sequencing
REmAb
Highest throughput: 50 to 100 mAbs per week
Highest accuracy: 100%
Lowest sample requirement: 50 μg
Most enzymes: 5-10 digests
Proprietary, next generation algorithms
Ile/Leu calls with WILD and WILDtag technology
Ability to handle the unexpected
Highest coverage: 100X
One sequence that works, every time

WILD® Isoleucine-Leucine Determination.

Isobaric combinations with confidence: our patented WILD® method was the first commercial service to use additional peptide fragmentation via electron transfer high collision energy dissociation (EThcD) to create and analyze w-ions. This enables true Isoleucine-Leucine determination based on experimental evidence alone. Our unique and patented WILDtag chemistry increases coverage and confidence in isobaric assignments.

WILD Isoluecine-Leucine determination allows us to obtain 100% accurate protein sequence with highest industry coverage

De Novo Sequencing of Any Isotype From Any Species.

We’ve worked with all isotypes and popular constructs, including bispecific, chimeric antibodies, nanobodies and fAbs. Secure 100% coverage of variable domains and obtain antibody sequences that recognize the right antigen with our de novo sequencing service.

World Leading Experts In De Novo Antibody Sequencing.

Our team comprises of experienced leaders in mass spectrometry proteomics, protein chemistry and bioinformatics. Even if your sample doesn’t meet our minimum requirements, come talk to us. REmAb® de novo antibody sequencing is an important tool for scientists in sequence analysis, particularly for the identification and characterization of novel antibodies.

Antibody Sequencing Success Stories.

“You are certainly the best CRO we’ve ever worked with!❤️”

Roya Servattalab, Scientist II, Marengo Therapeutics

“We’ve focused on coupling cytokines with highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to grant them into our platform and test in vitro and in vivo”

Pavel Khrimian, Co-Founder & CBO, Deka BioSciences

“Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target – and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands”

Matt Pope, Principal Scientist, SISCAPA
0+
antibody sequencing services completed since 2015. Here’s what our customers said 2-3 months after the project:
Happy

100% of survey respondents were happy with the experience

Refer

Survey respondents were 9.7/10 likely to refer their peers.

Early wins

85% of survey respondents were already successful downstream. Remainder were in progress. No reported failure.

The REmAb® Advantage.

  REmAb® Others
Throughput 50 to 100 mAbs per week Single runs
Accuracy 100% Often low / ambiguous
Sample volume requirement 50 μg of antibody protein (as low as 7μg) >150 μg
Multi-enzyme digest At least 5 – 10 enzymes 1 or 2
Bioinformatics software Proprietary, next generation algorithms Previous generation commercial software
Accurate Ile/Leu Determination Yes, WILD® and WILDtag technology Rarely
Ability to handle the unexpected Yes: additional chains, impurities, oligos, etc. Rarely
Depth of coverage 100X Low or patchy
Downstream impact One sequence that works, every time Costly ambiguities to express and test

Getting Started with Antibody Sequencing.

Requirements.

  • >50 μg of monoclonal antibody
  • >80% purity
  • Any isotype from any species

Is your antibody sample smaller or less pure? We’ve sequenced many mAbs when the sample amount was much less than our requirements.

Talk to a scientist about your sample.

Deliverables.

  • Complete antibody sequence in FASTA
  • Interactive peptide coverage viewer and report
  • Notable observations

Request a sample report

Turn-Around Time.

Rush, 1 week
1 sample, 2 wks
2-10 samples, 3 weeks
11+ samples, 4 weeks

Antibody Sequencing Pricing.

Intro Price

$5000per mAb
  • For any number of antibodies in the first order. We price match any equivalent offer.

Optional Add Ons.

Easy Purchasing Options.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.

REmAb® De Novo Antibody Sequencing Applications.

Antibody Sequencing, Discovery and Characterization Services.

Antibody Sequencing & Discovery Services.

REmAb® Protein Sequencing

Monoclonal antibody sequencing from small antibodysamples, no need for hybridoma or DNA information. Full sequence in record time.
Explore Antibody Sequencing Services

REpAb® pAb Sequencing

Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
Explore Polyclonal Antibody Sequencing

MATCHmAb

Antibody verification by rapid peptide mapping. Antibody sequence confirmation and full detailed mapping for development purposes.
Explore Peptide Mapping

RapidHDX-MS

Mass spec based epitope mapping. Epitope mapping for identify the binding site of an antibody to its corresponding antigen with the highest confidence and resolution.
Explore HDX-MS Epitope Mapping

RapidSPR Analysis

Label-free evaluation of antibody-antigen binding using surface plasmon resonance on Biacore or Nicoya. Can be employed for detailed kinetic profiling, kinetics screening, or epitope binning.
Explore SPR Analysis

Antibody Characterization

LC-MS analysis for study of antibody glycosylation, disulfide bonds, post-translational modifications, sequence variants, intact mass and size.
Explore antibody characterization